Gunnar Gårdemyr appointed CEO in Targovax

/in , , , /by

The board of Targovax is pleased to announce Mr. Gunnar Gårdemyr as the new CEO from January 12th, 2015.

Mr Gårdemyr has more than 30 years of international experience from the pharmaceutical and biotech industry. His experience includes management, business development, mergers & acquisitions, global marketing and commercial strategy. He holds the position as Corporate Advisor for Acino Pharma in Basel, Switzerland today. Prior to this position, he was Senior Vice President, Corporate Development/M&A, Global Business Development, Nycomed and Senior Vice President, Global Marketing, Takeda in Zurich, Switzerland, where he was in charge of the commercial assessment of external business development licensing opportunities.

Mr Gårdemyr started his career in Astra, followed by Ferring, Tigran Technologies and Retinalyze.

He has a Bachelor of Science in Business Administration and Economics from the University of Lund, Sweden.

Jónas Einarsson, Chairman of Targovax, says, “We are delighted to welcome Gunnar Gårdemyr to Targovax. Our ability to attract an experienced industry executive with Gunnar’s track record and knowledge reflects Targovax` potential. His leadership will accelerate the company’s further development”.

“We are very grateful to Hanne Mette D. Kristensen for her contribution by leading Targovax from establishment to a phase II company”, says Jónas Einarsson.

 

Facts:

Targovax
Targovax was established in October in 2010 to develop immunotherapy in the form of therapeutic cancer vaccines based on pioneering research at the Norwegian Radium Hospital and Norsk Hydro. Mutation of RAS is an early mutation in the transformation of a normal cell into a cancer cell. Lead candidate TG01 educates the body’s immune system to recognize and kill cancer cells with RAS mutations. TG01 has Orphan Drug status for pancreatic cancer in the EU and US and is currently in Phase II trials in operated pancreatic cancer, patients start treatment up to 12 weeks after surgery. The company is located in Lysaker, close to Oslo, Norway.
www.targovax.com